SG11201807827VA - Process for the preparation of pegylated drug-linkers and intermediates thereof - Google Patents
Process for the preparation of pegylated drug-linkers and intermediates thereofInfo
- Publication number
- SG11201807827VA SG11201807827VA SG11201807827VA SG11201807827VA SG11201807827VA SG 11201807827V A SG11201807827V A SG 11201807827VA SG 11201807827V A SG11201807827V A SG 11201807827VA SG 11201807827V A SG11201807827V A SG 11201807827VA SG 11201807827V A SG11201807827V A SG 11201807827VA
- Authority
- SG
- Singapore
- Prior art keywords
- bothell
- washington
- international
- drive
- pct
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108010044540 auristatin Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662313460P | 2016-03-25 | 2016-03-25 | |
PCT/US2017/024148 WO2017165851A1 (en) | 2016-03-25 | 2017-03-24 | Process for the preparation of pegylated drug-linkers and intermediates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807827VA true SG11201807827VA (en) | 2018-10-30 |
Family
ID=59900804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807827VA SG11201807827VA (en) | 2016-03-25 | 2017-03-24 | Process for the preparation of pegylated drug-linkers and intermediates thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US11844839B2 (zh) |
EP (1) | EP3433278A4 (zh) |
JP (4) | JP7073266B2 (zh) |
KR (2) | KR102626498B1 (zh) |
CN (1) | CN109843919A (zh) |
AU (1) | AU2017237186A1 (zh) |
BR (1) | BR112018069273A2 (zh) |
CA (1) | CA3017527A1 (zh) |
EA (1) | EA201892040A1 (zh) |
IL (2) | IL261759B (zh) |
MA (1) | MA43835A (zh) |
SG (1) | SG11201807827VA (zh) |
TW (1) | TWI790996B (zh) |
UA (1) | UA125510C2 (zh) |
WO (1) | WO2017165851A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3041254A1 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
SG10202104259RA (en) | 2016-11-08 | 2021-06-29 | Regeneron Pharma | Steroids and protein-conjugates thereof |
CA3045857A1 (en) | 2016-12-22 | 2018-06-28 | Universita Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
JP2020512312A (ja) * | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体 |
KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
MX2020004691A (es) * | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
SG11202010909RA (en) | 2018-05-09 | 2020-12-30 | Regeneron Pharma | Anti-msr1 antibodies and methods of use thereof |
WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
TW202015740A (zh) | 2018-06-07 | 2020-05-01 | 美商西雅圖遺傳學公司 | 喜樹鹼結合物 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2024108053A1 (en) | 2022-11-17 | 2024-05-23 | Sanofi | Ceacam5 antibody-drug conjugates and methods of use thereof |
Family Cites Families (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8504461A1 (es) | 1982-04-12 | 1985-04-16 | Hybritech Inc | Un procedimiento para obtener un polidoma. |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
FI102355B (fi) | 1988-02-11 | 1998-11-30 | Squibb Bristol Myers Co | Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi |
US5851527A (en) | 1988-04-18 | 1998-12-22 | Immunomedics, Inc. | Method for antibody targeting of therapeutic agents |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
FR2676058B1 (fr) | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
US6569834B1 (en) | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
DE69434136T2 (de) | 1993-10-01 | 2005-12-01 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin-derivate |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
JP2763020B2 (ja) | 1995-04-27 | 1998-06-11 | 日本電気株式会社 | 半導体パッケージ及び半導体装置 |
DE19516717A1 (de) | 1995-05-06 | 1996-11-07 | Basf Ag | Verfahren zur Herstellung von Diarylethanen |
US5756593A (en) | 1995-05-15 | 1998-05-26 | Enzon, Inc. | Method of preparing polyalkyene oxide carboxylic acids |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
DE69737867T2 (de) | 1996-05-03 | 2007-10-18 | Immunomedics, Inc. | Zielgerichtete kombinations-immuntherapie für krebs |
US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
PT964702E (pt) | 1996-08-02 | 2006-12-29 | Ortho Mcneil Pharm Inc | Polipéptidos tendo um único polímero solúvel em água ligado ao n-terminal por covalência |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
CA2282504A1 (en) | 1997-02-25 | 1998-08-27 | Jun-Ping Xu | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
CA2288994C (en) | 1997-04-30 | 2011-07-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
US20040009166A1 (en) | 1997-04-30 | 2004-01-15 | Filpula David R. | Single chain antigen-binding polypeptides for polymer conjugation |
EP1036164B1 (en) | 1997-11-21 | 2010-06-30 | Human Genome Sciences, Inc. | Chemokine alpha-5 |
GB2381103B (en) | 1997-12-17 | 2003-06-04 | Fujitsu Ltd | Memory access methods and devices for use with random access memories |
US5965119A (en) | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US7060479B2 (en) | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6214330B1 (en) | 1998-07-13 | 2001-04-10 | Enzon, Inc. | Coumarin and related aromatic-based polymeric prodrugs |
US6361774B1 (en) | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
US6323135B1 (en) | 1998-12-09 | 2001-11-27 | Advanced Micro Devices, Inc. | Method of forming reliable capped copper interconnects/with high etch selectivity to capping layer |
JP2000230000A (ja) | 1999-02-08 | 2000-08-22 | Hokkaido Univ | 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体 |
AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US6777387B2 (en) | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
AU2001272017A1 (en) | 2000-06-20 | 2002-01-02 | Immunomedics Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
US6906182B2 (en) | 2000-12-01 | 2005-06-14 | Cell Works Therapeutics, Inc. | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
JP4179771B2 (ja) | 2001-06-25 | 2008-11-12 | 株式会社デンソー | 自動車の乗員保護装置 |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
MXPA04004336A (es) | 2001-11-07 | 2005-05-16 | Nektar Therapeutics Al Corp | Polimeros ramificados y sus conjugados. |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
CN1638800A (zh) | 2002-01-09 | 2005-07-13 | 米德列斯公司 | 抗cd30的人类单克隆抗体 |
AU2003219796A1 (en) | 2002-02-20 | 2003-09-09 | Beth Israel Deaconess Medical Center | Conjugates comprising a biodegradable polymer and uses therefor |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
GB0218518D0 (en) | 2002-03-22 | 2002-09-18 | Aventis Pharma Inc | Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
US20050233949A1 (en) | 2002-04-12 | 2005-10-20 | Holick Michael F | Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof |
US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7413738B2 (en) | 2002-08-13 | 2008-08-19 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on biodegradable linkers |
WO2004044222A2 (en) | 2002-11-12 | 2004-05-27 | Enzon Pharmaceuticals, Inc. | Polymeric prodrugs of vancomycin |
WO2004044223A2 (en) | 2002-11-12 | 2004-05-27 | Enzon Pharmaceuticals, Inc. | Prodrugs of vancomycin with hydrolysis resistant polymer linkers |
DE10254439A1 (de) | 2002-11-21 | 2004-06-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Tubulysine, Herstellungsverfahren und Tubulysin-Mittel |
US7888536B2 (en) | 2004-02-13 | 2011-02-15 | Quanta Biodesign, Ltd. | Selective and specific preparation of discrete PEG compounds |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
RU2394041C2 (ru) | 2003-04-13 | 2010-07-10 | Энзон Фармасьютикалз, Инк. | Полимерные олигонуклеотидные пролекарства |
KR20060080535A (ko) | 2003-05-14 | 2006-07-10 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
US20060003412A1 (en) | 2003-12-08 | 2006-01-05 | Xencor, Inc. | Protein engineering with analogous contact environments |
AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
EP2087910B1 (en) | 2004-03-23 | 2022-05-04 | Ascendis Pharma GmbH | Polymeric prodrugs |
WO2005112919A2 (en) | 2004-05-19 | 2005-12-01 | Medarex, Inc. | Self-immolative linkers and drug conjugates |
JP2008519863A (ja) | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | N末端にアミノ安息香酸単位を有するオーリスタチン |
US20070134243A1 (en) | 2004-12-01 | 2007-06-14 | Gazzard Lewis J | Antibody drug conjugates and methods |
US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
AU2006210837B2 (en) | 2005-01-31 | 2012-07-12 | Genentech, Inc. | Anti-EphB2 antibodies and methods using same |
EP1857462B9 (en) | 2005-02-18 | 2013-02-13 | Nof Corporation | Polyoxyalkylene derivative |
EP2511299A1 (en) | 2005-04-19 | 2012-10-17 | Seattle Genetics, Inc. | Humanized anti-CD70 binding agents and uses thereof |
US8132476B2 (en) | 2005-06-20 | 2012-03-13 | Hy-Energy, Llc | Method and apparatus for handling small quantities of fluids |
US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
WO2007011968A2 (en) | 2005-07-18 | 2007-01-25 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
US20110014151A1 (en) | 2006-01-11 | 2011-01-20 | Biotech Igg Ab | Macromolecule conjugate |
EP1813614B1 (en) | 2006-01-25 | 2011-10-05 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives |
US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
US8257706B2 (en) | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
KR20090057235A (ko) | 2006-09-15 | 2009-06-04 | 엔존 파마슈티컬즈, 인코포레이티드 | 리신계 폴리머 링커 |
CA2662520A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
US8367065B2 (en) | 2006-09-15 | 2013-02-05 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
CA2662981A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Targeted polymeric prodrugs containing multifunctional linkers |
EP2368908A3 (en) | 2006-11-10 | 2011-10-12 | CovX Technologies Ireland Limited | Anti- angiogenic compounds |
WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
US7884869B2 (en) | 2007-04-30 | 2011-02-08 | Motorola Mobility, Inc. | Assignment of pixel element exposure times in digital camera modules and mobile communication devices |
EP2176293B1 (en) | 2007-06-25 | 2019-04-03 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
WO2009009716A1 (en) | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery systems containing an aromatic allylic acid |
WO2009009712A1 (en) | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
US20110263650A1 (en) | 2007-07-20 | 2011-10-27 | Helmholtz-Zentrum Für Infektions-Forschung Gmbh | Tubulysin D Analogues |
MX2010001955A (es) | 2007-08-20 | 2010-03-10 | Enzon Pharmaceuticals Inc | Enlazadores polimericos que contienen porciones de disulfuro-piridilo. |
EP2211904B1 (en) | 2007-10-19 | 2016-08-17 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
WO2009117531A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
EP2174947A1 (en) | 2008-09-25 | 2010-04-14 | Universität des Saarlandes | Bioactive pre-tubulysins and use thereof |
EP2341774B1 (en) | 2008-10-21 | 2013-12-04 | Belrose Pharma Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
CA2749115C (en) | 2009-01-09 | 2022-06-21 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
EP2385950B1 (en) | 2009-01-12 | 2014-03-12 | University Of Washington | Method for 2-sulfation of glycosides |
ES2604668T3 (es) | 2009-02-05 | 2017-03-08 | Immunogen, Inc. | Nuevos derivados de benzodiacepina |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス, インコーポレイテッド | Dr5リガンド薬物結合体 |
KR20120080611A (ko) | 2009-10-06 | 2012-07-17 | 이뮤노젠 아이엔씨 | 효능 있는 접합체 및 친수성 링커 |
ES2581207T3 (es) | 2009-11-12 | 2016-09-02 | Tube Pharmaceuticals Gmbh | Inhibidores de la tubulina |
EP2322537A1 (en) | 2009-11-12 | 2011-05-18 | R & D Biopharmaceuticals Gmbh | Tubulin inhibitors |
EP2509421B1 (en) | 2009-12-10 | 2020-02-05 | Cedars-Sinai Medical Center | Drug delivery of temozolomide for systemic based treatment of cancer |
EP3395361A1 (en) | 2010-02-08 | 2018-10-31 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
ES2581314T3 (es) | 2010-03-02 | 2016-09-05 | Seattle Genetics, Inc. | Métodos de cribado de anticuerpos |
WO2011120053A1 (en) | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
WO2011130613A1 (en) | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
EP2662095A1 (en) | 2010-04-15 | 2013-11-13 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
EP2789622B1 (en) | 2010-04-15 | 2017-03-01 | MedImmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
CN102869254A (zh) | 2010-04-16 | 2013-01-09 | 安龙制药公司 | 腺嘌呤核苷酸类似物聚合共轭物 |
EP2409983A1 (en) | 2010-07-19 | 2012-01-25 | Leibniz-Institut für Pflanzenbiochemie (IPB) | Tubulysin analogues |
DK3461847T3 (da) | 2010-12-06 | 2020-12-14 | Seagen Inc | Humaniserede antistoffer mod LIV-1 og anvendelse heraf til behandling af cancer |
SG10202007640VA (en) | 2011-02-15 | 2020-09-29 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
PL2678037T3 (pl) | 2011-02-25 | 2015-05-29 | Lonza Ag | Rozgałęziony łącznik do koniugatów białko-lek. |
CN110078787A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
EP2750681B1 (en) | 2011-08-30 | 2020-05-27 | Quanta Biodesign, Ltd. | Branched discrete peg constructs |
EP2751120B1 (en) | 2011-09-20 | 2018-08-22 | MedImmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
KR101961976B1 (ko) | 2011-10-14 | 2019-03-25 | 시애틀 지네틱스, 인크. | 피롤로벤조디아제핀 및 표적 접합체 |
EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
CN108164551A (zh) | 2011-10-14 | 2018-06-15 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
CN104220094A (zh) | 2012-02-17 | 2014-12-17 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
US20130225789A1 (en) | 2012-02-29 | 2013-08-29 | Yi Sun | Polyethylene Glycol Having Hetero Multiple Functional Groups |
CA2873112A1 (en) | 2012-05-11 | 2013-11-14 | Alexander Krantz | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物,偶联方法,及其用途 |
CN108465112B (zh) | 2012-05-15 | 2022-04-29 | 西雅图基因公司 | 自稳定接头偶联物 |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
US9650331B2 (en) | 2012-06-18 | 2017-05-16 | Polytherics Limited | Conjugation reagents |
ES2782248T3 (es) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila |
JP6328648B2 (ja) | 2012-10-24 | 2018-05-23 | ポリセリックス・リミテッド | 新規薬物−タンパク質コンジュゲート |
CN105142674B (zh) | 2013-03-13 | 2018-11-13 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓和其结合物 |
NZ710929A (en) | 2013-03-15 | 2018-02-23 | Novartis Ag | Antibody drug conjugates |
US9430462B2 (en) | 2013-07-30 | 2016-08-30 | Edanz Group Ltd. | Guided article authorship |
NZ717668A (en) * | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
IL301674A (en) * | 2013-12-19 | 2023-05-01 | Seagen Inc | Methylene carbamate binders for use with drug-targeting conjugates |
EP3900742B1 (en) | 2014-09-11 | 2024-05-15 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
DK3270965T3 (da) | 2015-03-18 | 2020-06-08 | Seattle Genetics Inc | Cd48-antistoffer og konjugater deraf |
CN109562152B (zh) | 2016-08-09 | 2024-04-02 | 西雅图基因公司 | 含有具有改善的生理化学性质的自稳定性接头的药物缀合物 |
JP2020512312A (ja) | 2017-03-24 | 2020-04-23 | シアトル ジェネティックス, インコーポレイテッド | グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体 |
-
2017
- 2017-03-24 CA CA3017527A patent/CA3017527A1/en active Pending
- 2017-03-24 JP JP2018548056A patent/JP7073266B2/ja active Active
- 2017-03-24 US US16/088,235 patent/US11844839B2/en active Active
- 2017-03-24 AU AU2017237186A patent/AU2017237186A1/en active Pending
- 2017-03-24 BR BR112018069273A patent/BR112018069273A2/pt unknown
- 2017-03-24 UA UAA201810087A patent/UA125510C2/uk unknown
- 2017-03-24 CN CN201780026818.2A patent/CN109843919A/zh active Pending
- 2017-03-24 MA MA043835A patent/MA43835A/fr unknown
- 2017-03-24 EA EA201892040A patent/EA201892040A1/ru unknown
- 2017-03-24 WO PCT/US2017/024148 patent/WO2017165851A1/en active Application Filing
- 2017-03-24 KR KR1020237031301A patent/KR102626498B1/ko active IP Right Grant
- 2017-03-24 EP EP17771293.2A patent/EP3433278A4/en active Pending
- 2017-03-24 KR KR1020187030463A patent/KR20180134351A/ko not_active IP Right Cessation
- 2017-03-24 SG SG11201807827VA patent/SG11201807827VA/en unknown
- 2017-03-27 TW TW106110181A patent/TWI790996B/zh active
-
2018
- 2018-09-13 IL IL261759A patent/IL261759B/en unknown
-
2020
- 2020-03-24 JP JP2020053136A patent/JP2020100669A/ja active Pending
-
2021
- 2021-10-10 IL IL287140A patent/IL287140A/en unknown
-
2022
- 2022-04-08 JP JP2022064462A patent/JP2022082777A/ja active Pending
-
2023
- 2023-06-05 JP JP2023092604A patent/JP2023106627A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201735919A (zh) | 2017-10-16 |
IL287140A (en) | 2021-12-01 |
TW202325718A (zh) | 2023-07-01 |
EP3433278A1 (en) | 2019-01-30 |
EP3433278A4 (en) | 2019-11-06 |
IL261759B (en) | 2021-10-31 |
AU2017237186A1 (en) | 2018-11-01 |
JP2019512492A (ja) | 2019-05-16 |
CN109843919A (zh) | 2019-06-04 |
JP2022082777A (ja) | 2022-06-02 |
JP2020100669A (ja) | 2020-07-02 |
US11844839B2 (en) | 2023-12-19 |
KR102626498B1 (ko) | 2024-01-19 |
TWI790996B (zh) | 2023-02-01 |
UA125510C2 (uk) | 2022-04-13 |
KR20180134351A (ko) | 2018-12-18 |
KR20230135169A (ko) | 2023-09-22 |
BR112018069273A2 (pt) | 2019-01-22 |
JP7073266B2 (ja) | 2022-05-23 |
JP2023106627A (ja) | 2023-08-01 |
US20190388546A1 (en) | 2019-12-26 |
WO2017165851A1 (en) | 2017-09-28 |
MA43835A (fr) | 2018-11-28 |
CA3017527A1 (en) | 2017-09-28 |
EA201892040A1 (ru) | 2019-04-30 |
IL261759A (en) | 2018-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
SG11201908275XA (en) | Peptides and methods for the treatment of diabetes |